Premium
Oral Glutamine Reduces Radiation Morbidity in Breast Conservation Surgery
Author(s) -
Rubio Isabel,
Suva Larry J.,
Todorova Valentina,
Bhattacharyya Sudeepa,
Kaufmann Yihong,
Maners Anne,
Smith Maureen,
Klimberg V. Suzanne
Publication year - 2013
Publication title -
journal of parenteral and enteral nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.935
H-Index - 98
eISSN - 1941-2444
pISSN - 0148-6071
DOI - 10.1177/0148607112474994
Subject(s) - medicine , breast cancer , glutamine , glutathione , placebo , radiation therapy , gastroenterology , oncology , amino acid , surgery , cancer , pathology , biochemistry , chemistry , alternative medicine , enzyme
This study examined the effect of oral glutamine (Gln) on radiation injury in breast cancer patients undergoing radiation therapy. The radiation injury was evaluated using Radiation Therapy Oncology Group (RTOG) scales. Cosmesis was scored. Blood Gln and glutathione (GSH) levels were determined. Serum protein profiling was determined using surface‐enhanced laser desorption/ionization time‐of‐flight mass spectrometry (SELDI‐TOF MS). Patients receiving Gln scored significantly better in RTOG score than the patients receiving placebo. Cosmetic scores averaged excellent in the Gln group vs fair to good in the placebo group. Blood Gln and GSH levels were significantly higher in the Gln group vs the placebo group. Serum protein profiling with SELDI‐TOF MS identified a novel Gln‐responsive protein that showed amino acid similarity with myoglobin. These results suggest that Gln is an effective way to reduce radiation morbidity to breast cancer and is associated with the increased expression of a novel serum protein biomarker.